isv facebook isv linkedin
The International Society for Vaccines is an organization that engages, supports, and sustains the professional goals of a diverse membership in all areas relevant to vaccines - 2019 ISV Annual Congress

 nature logo

Bringing Vaccinologists Together

"The International Society for Vaccines is uniting the diverse community of vaccinologists."

 Focal Point on Vaccine Research in Asia

Look East for the Future of Vaccine Research  

  

2018 ISV PAPER OF THE YEAR

ISV Newsletters

2019   2018   2017   2016   2015

 

2019 President's Corner

Dr WeinerISV began 2019 by implementing a new membership platform with expanded functionality powered by YourMembership.com®.  Your active participation in ISV activities is greatly encouraged.  Please consider renewing your ISV membership or joining as a new member.  Full membership terms are 1, 3 or 5 years; postdoc or graduate student terms are for one year at a reduced rate.  You may now easily maintain your profile and reset your password or request your username in real time.  Additional enhancements to the member portal will be rolled out in the months ahead.

Member benefits include a registration discount of US$100 for the 2019 ISV Annual Congress.  The ISV annual general meeting is held as part of the Annual Congress to determine key ISV policies and elect members of the ISV Executive Board.  Participation in ISV is an excellent way to increase your scientific network and visibility.

This year's Annual Congress takes place October 27-29, 2019 in Ghent, Belgium, led by Ted Ross (US) and Linda Klavinskis (UK) along with local co-Chair Xavier Saelens (University of Ghent, Belgium).  Working with an outstanding Scientific Committee (www.ISVcongress.org), several leaders in high profile vaccine topics have been invited to speak at this year's meeting.  In addition to the invited keynote speakers, a sizable number of speakers will be selected from the submitted abstracts.  Special efforts are made to help trainees advance their careers with a career development panel discussion, feedback of poster presentations by senior scientists, and ISV's mentoring program.  Abstract submission and registration will begin soon at www.ISVcongress.org.

The New York Times recently published an article in their travel section highlighting Ghent: (www.nytimes.com).  Ghent is centrally located in Europe, at the crossroads of transport networks between Amsterdam, Paris, London and the Ruhr area of Germany.  The city is also easily accessible by air via Brussels airport and a direct train connection.  Ghent and its surroundings are home to a vibrant vaccine and bioscience community of universities, biotechnology institutes, pharmaceutical companies and biotech SME's.  The city has an impressive history going back 15 centuries and is home to famous museums and historical buildings straddling idyllic canals, all within walking distance of hotels and restaurants.

We are pleased to announce the 2018 ISV Paper of the Year voted by ISV Fellows, ISV Executive Board members and ISV Outreach Committee members is Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis, lead author Van Der Meeren, published in the New England Journal of Medicine: https://www.ncbi.nlm.nih.gov/pubmed/30280651

 David B. Weiner, President, ISV